Nektar Therapeutics
NKTR · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Mar 2026
Open the dashboardInfographicSummary
FY2025 key figures
| $ | FY2025 | FY2024 | Change |
|---|---|---|---|
| Revenue | $55.2M | $98.4M | −43.9% |
| Operating income | −$140M | −$105M | −33.2% |
| Net income | −$164M | −$119M | −37.9% |
Latest quarter: Q3 2026
Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 13, 2026
| $ | Q3 2026 | Year earlier | Change |
|---|---|---|---|
| Revenue | $9.40M | $11.8M | −20.3% |
| Operating income | −$57.8M | −$31.7M | −82.3% |
| Net income | −$55.7M | −$35.5M | −56.9% |
Q3 2026 dashboardQ3 2026 infographic
Questions
- What was Nektar's revenue in FY2025?
- $55.2M in FY2025 (Fiscal year ended Dec 31, 2025), −43.9% vs $98.4M a year earlier, per its 10-K filed Mar 2026.
- Was Nektar profitable in FY2025?
- No: net income was −$164M and operating income −$140M in FY2025.
- What was Nektar's revenue in Q3 2026?
- $9.40M (−20.3% vs a year earlier), per its Form 10-Q filed Nov 13, 2026.